These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 36184757)

  • 1. Real world experience of brodalumab treatment in patients with moderate-to-severe plaque psoriasis in the Greek population: Results from an interim analysis of the BrIDGE study.
    Rigopoulos D; Angelakopoulos C; Apalla Z; Georgiou S; Delli F; Drosos A; Zafiriou E; Katsantonis J; Lazaridou E; Panagakis P; Papadavid E; Papakonstantis M; Roussaki-Schulze AV; Sotiriou E; Anastasiadis G; Tampouratzi E; Chasapi V; Sfaelos K; Ioannides D;
    Dermatol Ther; 2022 Dec; 35(12):e15886. PubMed ID: 36184757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world data on the effectiveness of brodalumab in patients with moderate-to severe plaque psoriasis in the Greek clinical setting (the BrIDGE study).
    Rigopoulos D; Tampouratzi E; Angelakopoulos C; Apalla Z; Barkis I; Georgiou S; Delli F; Drosos A; Zafiriou E; Katsantonis J; Lazaridou E; Panagakis P; Papadavid E; Papakonstantis M; Roussaki-Schulze AV; Sotiriou E; Anastasiadis G; Chasapi V; Sfaelos K; Ioannides D;
    J Eur Acad Dermatol Venereol; 2024 Jun; 38(6):1121-1130. PubMed ID: 38308561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical evidence on the use of brodalumab for the treatment of psoriasis in Greece: Experience from clinical practice of four tertiary hospitals.
    Tampouratzi E; Papakonstantis M; Katsantonis J; Sidiropoulos T; Delli F; Efthymiadis K; Sfaelos K; Christodoulou A; Chasapi V; Panagakis P
    Dermatol Ther; 2022 Jul; 35(7):e15532. PubMed ID: 35451147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI; Hooft L
    Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study.
    Nakagawa H; Niiro H; Ootaki K;
    J Dermatol Sci; 2016 Jan; 81(1):44-52. PubMed ID: 26547109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of brodalumab in the Korean population for the treatment of moderate to severe plaque psoriasis: A randomized, phase III, double-blind, placebo-controlled study.
    Seo SJ; Shin BS; Lee JH; Jeong H
    J Dermatol; 2021 Jun; 48(6):807-817. PubMed ID: 33373480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2/-3 Randomized Trials.
    McMichael A; Desai SR; Qureshi A; Rastogi S; Alexis AF
    Am J Clin Dermatol; 2019 Apr; 20(2):267-276. PubMed ID: 30471012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study.
    Lebwohl MG; Blauvelt A; Menter A; Papp KA; Guenthner S; Pillai R; Israel RJ; Jacobson A
    Am J Clin Dermatol; 2019 Dec; 20(6):863-871. PubMed ID: 31493163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis.
    Viswanathan HN; Mutebi A; Milmont CE; Gordon K; Wilson H; Zhang H; Klekotka PA; Revicki DA; Augustin M; Kricorian G; Nirula A; Strober B
    Value Health; 2017 Sep; 20(8):1174-1179. PubMed ID: 28964451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world clinical outcomes of treatment with brodalumab in patients with moderate-to-severe psoriasis: a retrospective, 24-month experience from four academic dermatology centers in Greece.
    Papadavid E; Zafeiriou E; Georgiou S; Roussaki-Schulze AV; Spiliopoulos T; Vryzaki E; Oikonomou C; Drongoula O; Boziou M; Goudouras G; Sfaelos K; Apalla Z; Lazaridou E
    J Dermatolog Treat; 2022 Nov; 33(7):3053-3059. PubMed ID: 36000186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single-center retrospective study in a real-life setting.
    Megna M; Potestio L; Camela E; Fabbrocini G; Ruggiero A
    Dermatol Ther; 2022 Sep; 35(9):e15667. PubMed ID: 35762107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.
    Tada Y; Watanabe R; Noma H; Kanai Y; Nomura T; Kaneko K
    J Dermatol Sci; 2020 Jul; 99(1):53-61. PubMed ID: 32600737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
    Menter A; Gordon K; Carey W; Hamilton T; Glazer S; Caro I; Li N; Gulliver W
    Arch Dermatol; 2005 Jan; 141(1):31-8. PubMed ID: 15655139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brodalumab for the treatment of moderate-to-severe plaque-type psoriasis: a real-life, retrospective 24-week experience.
    Fargnoli MC; Esposito M; Dapavo P; Parodi A; Rossi M; Tiberio R; Dastoli S; Offidani AM; Argenziano G; Gisondi P; Lo Schiavo A; Loconsole F; Pella P; Bardazzi F; Cusano F; Gattoni M; Nacca M; Cannavò SP; Pellegrini C; Costanzo A;
    J Eur Acad Dermatol Venereol; 2021 Mar; 35(3):693-700. PubMed ID: 32916767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3.
    Papp KA; Gordon KB; Langley RG; Lebwohl MG; Gottlieb AB; Rastogi S; Pillai R; Israel RJ
    Br J Dermatol; 2018 Aug; 179(2):320-328. PubMed ID: 29488226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brodalumab for Plaque Psoriasis: A Canadian Real-World Experience at 2-Years Post-Launch.
    Gaudet V; Yap B; Hassan S; Barbeau M
    J Cutan Med Surg; 2023; 27(3):226-235. PubMed ID: 37083148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis.
    Papp KA; Reich K; Paul C; Blauvelt A; Baran W; Bolduc C; Toth D; Langley RG; Cather J; Gottlieb AB; Thaçi D; Krueger JG; Russell CB; Milmont CE; Li J; Klekotka PA; Kricorian G; Nirula A
    Br J Dermatol; 2016 Aug; 175(2):273-86. PubMed ID: 26914406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Data on Brodalumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: An Observational Study from the Czech Republic BIOREP Registry.
    Kojanova M; Turkova B; Gkalpakiotis S; Cetkovska P; Fialova J; Dolezal T; Machovcova A; Apol ED;
    Adv Ther; 2024 Oct; 41(10):3951-3971. PubMed ID: 39207667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in psoriasis signs and symptom severity between patients with clear and almost clear skin in clinical practice.
    Feldman SR; Bushnell DM; Klekotka PA; Scanlon M; Martin ML; Wade SW; Yang W; Pinto L; Kircik L; Viswanathan HN
    J Dermatolog Treat; 2016; 27(3):224-7. PubMed ID: 26447179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Real-Life 208 Week Single-Centred, Register-Based Retrospective Study Assessing Secukinumab Survival and Long-Term Efficacy and Safety Among Greek Patients with Moderate to Severe Plaque Psoriasis, Including Difficult-to-Treat Manifestations Such as Genitals and Scalp.
    Kyrmanidou E; Kemanetzi C; Stavros C; Trakatelli MG; Patsatsi A; Madia X; Ignatiadi D; Kalloniati E; Apalla Z; Lazaridou E
    Dermatol Pract Concept; 2024 Apr; 14(2):. PubMed ID: 38810083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.